Pediatric Market Access PolyVascular offers the only non-surgical pulmonary valve and delivery system for children as young as two, enabling less invasive treatment and improved quality of life. This creates sales opportunities with pediatric cardiology departments, congenital heart disease programs, and major hospital systems that manage CHD patients. Action steps include mapping CHD programs, identifying clinical champions, and proposing pilot or bundled procurement with clinician training.

Validation Momentum External validation from NIH SBIR Phase IIb funding and American Heart Association Health Tech Competition wins strengthens the case for pilots and co-funded trials. Leverage these milestones in discussions with hospital procurement, grant offices, and academic partners to accelerate adoption and fund initial implementations.

Growth Value Growing with the patient is a key value prop—the valve expands as the child grows and reduces repeated open-heart surgeries. Position this as a long-term ROI to procurement teams and payers, and target centers with large pediatric surgery volumes. Align outreach with surgeons and interventionalists to map the clinical adoption path and training needs.

Competitive Differentiation Biocompatible polymer-based design aims to reduce endocarditis risk and immune sensitization compared with animal or human tissue grafts. Use this differentiation in competitive conversations and collect clinical data to strengthen the value proposition. Highlight ease of manufacturing and scalable production as a supply advantage in supplier discussions.

Go To Market Strong market visibility through conferences and press coverage, plus regional proximity in Houston, supports partnerships with distributors, larger medtech players, or licensing opportunities. Prioritize outreach to hospital systems with robust pediatric CHD programs, pursue co-development or distribution deals, and plan expansion beyond Texas leveraging ongoing funding and awards.